Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron Sargeant

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Toxicologic Pathology|February 2, 2023
Cardiac Rhabdomyoma in Four Göttingen MinipigsLaine E Feller, Aaron Sargeant, E J Ehrhart, et al.
Leukemia Research|August 2, 2011
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphomaBevin Zimmerman, Aaron Sargeant, Kristina Landes, et al.
Leukemia Research|December 17, 2009
OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathwaysLi-Yuan Bai, Jing-Ru Weng, Chen-Hsun Tsai, et al.
International Journal of Toxicology|April 5, 2021
Proposal to Eliminate Urethane-Treated Positive Control Dose Groups in 26-Week Tg.rasH2 Carcinogenicity StudiesMadhav G Paranjpe, Daniel Rudmann, Aaron Sargeant, et al.
Toxicologic Pathology|December 8, 2020
Using Deep Learning Artificial Intelligence Algorithms to Verify N-Nitroso-N-Methylurea and Urethane Positive Control Proliferative Changes in Tg-RasH2 Mouse Carcinogenicity StudiesDaniel Rudmann, Jay Albretsen, Colin Doolan, et al.
Toxicologic Pathology|August 11, 2018
Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical ProductsArmando R Irizarry Rovira, Bindu M Bennet, Brad Bolon, et al.
Cancer Research|August 19, 2007
A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cellsJing-Ru Weng, Chen-Hsun Tsai, Samuel K Kulp, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Toxicologic Pathology|February 2, 2023
Cardiac Rhabdomyoma in Four Göttingen MinipigsLaine E Feller, Aaron Sargeant, E J Ehrhart, et al.
Leukemia Research|August 2, 2011
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphomaBevin Zimmerman, Aaron Sargeant, Kristina Landes, et al.
Leukemia Research|December 17, 2009
OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathwaysLi-Yuan Bai, Jing-Ru Weng, Chen-Hsun Tsai, et al.
International Journal of Toxicology|April 5, 2021
Proposal to Eliminate Urethane-Treated Positive Control Dose Groups in 26-Week Tg.rasH2 Carcinogenicity StudiesMadhav G Paranjpe, Daniel Rudmann, Aaron Sargeant, et al.
Toxicologic Pathology|December 8, 2020
Using Deep Learning Artificial Intelligence Algorithms to Verify N-Nitroso-N-Methylurea and Urethane Positive Control Proliferative Changes in Tg-RasH2 Mouse Carcinogenicity StudiesDaniel Rudmann, Jay Albretsen, Colin Doolan, et al.
Toxicologic Pathology|August 11, 2018
Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical ProductsArmando R Irizarry Rovira, Bindu M Bennet, Brad Bolon, et al.
Cancer Research|August 19, 2007
A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cellsJing-Ru Weng, Chen-Hsun Tsai, Samuel K Kulp, et al.
Pageof 1